Canaccord Genuity Maintains Buy on Verona Pharma, Raises Price Target to $72

Benzinga · 02/12 13:59
Canaccord Genuity analyst Edward Nash maintains Verona Pharma (NASDAQ:VRNA) with a Buy and raises the price target from $44 to $72.